📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
142 announcements match the current filters (relevance ≥ 5).
Biocon Biologics Secures Europe Entry for Denosumab Biosimilars Starting Dec 2, 2025
Biocon Biologics has settled with Amgen Inc., clearing the path to commercialize its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and the rest of the world starting December 2, 2025. This follows the European Commission's approval in July 2025 and a previous settlement for the U.S. market. The products target significant markets, including 32 million osteoporosis patients in Europe and oncology-related bone health, strengthening Biocon's global biosimilar portfolio of 10 commercialized assets.
Key Highlights
Settlement with Amgen allows market entry for Denosumab biosimilars in Europe from December 2, 2025.
Commercialization includes Vevzuo® for oncology and Evfraxy® for osteoporosis and bone loss.
Targets a European market of 32 million individuals aged 50+ with osteoporosis and 2.74 million annual cancer cases.
Follows prior U.S. market entry settlements, broadening Biocon's reach in the oncology and bone health therapeutic areas.
Biocon Biologics currently serves over 6 million patients across 120+ countries with 10 commercialized biosimilars.
👀 What to Watch
Investors should monitor the revenue ramp-up from these launches in late 2025, as they represent a significant expansion into the high-value European biosimilars market. The resolution of legal hurdles with Amgen reduces uncertainty regarding Biocon's global commercialization timeline.
IOC Announces Senior Management Change
Indian Oil Corporation Limited (IOC) has announced the superannuation of Shri Subrata Chaudhuri, Executive Director-Finance, Refineries Headquarters, from the services of the Company on November 30, 2025. This disclosure is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The announcement relates to personnel one level below the Board of Directors. This change in senior management could have implications for the company's financial strategies.
Key Highlights
Shri Subrata Chaudhuri superannuated on November 30, 2025
Shri Subrata Chaudhuri was the Executive Director-Finance, Refineries Headquarters
Disclosure under Regulation 30 of SEBI Regulations 2015
👀 What to Watch
Investors should monitor upcoming financial reports and strategic decisions to assess the impact of this management change. Keep an eye on any further announcements regarding the appointment of a successor.
